Abbott Laboratories
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Abbott Laboratories (ABT). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Medical Devices | $4.90B 47.3% | $5.37B 48.2% | $5.54B 49.6% | $5.85B 46.5% |
| Diagnostic Products | $2.05B 19.8% | $2.17B 19.5% | $2.18B 19.5% | $3.09B 24.6% |
| Nutritional Products | $2.15B 20.7% | $2.21B 19.9% | $2.02B 18.1% | $2.14B 17.0% |
| Established Pharmaceuticals | $1.26B 12.2% | $1.38B 12.4% | $1.43B 12.8% | $1.50B 11.9% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Medical Devices | $1.61B 32.9% | $1.80B 33.5% | $1.89B 34.2% | $1.97B 33.6% |
| Diagnostic Products | $359.0M 17.5% | $372.0M 17.1% | $335.0M 15.4% | $499.0M 16.1% |
| Nutritional Products | $394.0M 18.4% | $418.0M 18.9% | $311.0M 15.4% | $368.0M 17.2% |
| Established Pharmaceuticals | $298.0M 23.7% | $346.0M 25.0% | $365.0M 25.6% | $382.0M 25.5% |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by region
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| International | $6.19B 59.8% | $6.87B 61.6% | $6.89B 61.7% | $7.38B 58.6% |
| United States | $4.17B 40.2% | $4.28B 38.4% | $4.27B 38.3% | $5.22B 41.4% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Operating metrics
Operating metrics are the figures a company uses to measure its own business — customer counts, stores, deliveries or the churn rate. None of them appear in the financial statements, and they often explain earlier than revenue does why revenue is moving.
| Metric | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Remaining performance obligations - Diagnostic Products | $5.90B | $6.00B | $6.20B | $6.20B +5.1% |
| Remaining performance obligations - Medical Devices | $427.0M | $436.0M | $429.0M | $455.0M +6.6% |
These metrics are not part of the financial statements; they sit in the narrative text of the filings. We read them out of the SEC filings using artificial intelligence and check every single figure against the original passage in the report; anything that is not found there verbatim is discarded. Source: SEC EDGAR (annual and quarterly reports, 10-K/10-Q).
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.